Novartis (NYSE:NVS) Stock Rating Upgraded by Wall Street Zen

Novartis (NYSE:NVS) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

NVS has been the topic of a number of other reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Thursday, October 22nd. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a report on Wednesday, July 22nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Novartis in a research note on Wednesday. Bank of America reiterated a “buy” rating on shares of Novartis in a report on Tuesday, September 8th. Finally, The Goldman Sachs Group reiterated a “sell” rating on shares of Novartis in a research note on Monday, September 21st. Six analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $152.25.

Novartis Trading Down 0.1%

Shares of NVS stock opened at $160.67 on Friday. The firm has a market capitalization of $306.58 billion, a P/E ratio of 30.66, a price-to-earnings-growth ratio of 2.96 and a beta of 0.41. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98. Novartis has a 1 year low of $122.57 and a 1 year high of $170.46. The firm’s fifty day simple moving average is $148.41 and its 200 day simple moving average is $151.80.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. During the same period in the prior year, the business earned $2.25 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, sell-side analysts predict that Novartis will post 9.04 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Highland Investment Advisors LLC purchased a new position in Novartis in the second quarter valued at about $25,000. Evolution Wealth Management Inc. grew its stake in Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after acquiring an additional 138 shares during the period. Atlatl Advisers LLC acquired a new stake in shares of Novartis in the second quarter valued at approximately $26,000. Archer Investment Corp lifted its stake in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after acquiring an additional 80 shares during the last quarter. Finally, Silicon Valley Capital Partners grew its stake in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock valued at $30,000 after buying an additional 161 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis News Summary

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis received a Zacks Rank #2 (Buy), reflecting improved expectations for its earnings prospects. The upgrade could provide near-term support for the shares. Novartis Rating Upgrade to Buy
• Positive Sentiment: Zacks also identified NVS as a strong long-term momentum stock, highlighting favorable style and performance characteristics that may attract growth and momentum investors. Novartis Top Momentum Stock
• Positive Sentiment: Novartis’s third-quarter results exceeded consensus expectations, with earnings per share of $2.46 versus $2.25 expected and revenue of $15.03 billion versus $14.53 billion expected. Revenue increased 4.4% year over year, supporting the company’s fundamental outlook. Novartis Q3 2026 Earnings Call Transcript
• Neutral Sentiment: DZ Bank initiated coverage with a Hold rating, signaling a balanced view of Novartis’s earnings strength and valuation. DZ Bank Novartis Coverage
• Negative Sentiment: Deutsche Bank downgraded Novartis from Hold to Sell, adding direct analyst pressure to the stock and countering the more favorable Zacks assessment. Deutsche Bank Downgrades Novartis
• Negative Sentiment: Analysts reduced peak-sales forecasts for remibrutinib after a late-stage multiple-sclerosis trial met its primary endpoint but appeared weaker than expected. The development raises concerns about the drug’s ability to offset upcoming patent-related revenue pressure. Novartis Remibrutinib and Patent Cliff
• Negative Sentiment: Erste Group Bank forecast weaker earnings for Novartis, adding to concerns that future results may not match the company’s recent quarterly beat. Erste Group Predicts Weaker Novartis Earnings

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.